Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Dana-Farber Cancer Institute

Reviewed by TrialFinderData Editorial Team · Updated

9 clinical trials · 9 recruiting · OTHER

Dana-Farber Cancer Institute has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Dana-Farber Cancer Institute\'s Trial Portfolio

Dana-Farber Cancer Institute is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Dana-Farber Cancer Institute's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Dana-Farber Cancer Institute's research footprint spans Prostate Cancer (2 trials), Mesothelioma (2), and Kidney Cancer (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Dana-Farber Cancer Institute's portfolio at 78% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Dana-Farber Cancer Institute

RECRUITINGNCT06202183

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 841 location
Colorectal CancerMetastatic Colon CancerMetastatic Colorectal Cancer
RECRUITINGNCT04997096

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving...

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 301 location
Ovarian CancerOvarian CarcinomaOvarian Cancer Stage IV+4
RECRUITINGPhase 1NCT06152809

CIML NK Cells With Venetoclax for AML

The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 102 locations
Acute Myeloid LeukemiaAcute Myeloid Leukemia RecurrentLeukemia+1
RECRUITINGNCT05080166

UPLYFT For Lymphoma Survivors

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 741 location
LymphomaSurvivorship
RECRUITINGNCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 3972 locations
Pancreas CancerLung CancerRenal Cancer+10
RECRUITINGPhase 2NCT07397611

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 323 locations
Renal Cell CarcinomaKidney CancerKidney Neoplasm+1
RECRUITINGNCT05899361

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 101 location
Urologic CancerUrologic NeoplasmsBladder Cancer+5
RECRUITINGNCT02747888

Hereditary Risk Factors for Thyroid Cancer

Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 2501 location
Thyroid Cancer
RECRUITINGNCT03683680

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Sponsor: Dana-Farber Cancer InstituteEnrolling: 2401 location
Mesothelioma

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Dana-Farber Cancer Institute have on ClinicalTrials.gov?

Dana-Farber Cancer Institute has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Dana-Farber Cancer Institute study?

Dana-Farber Cancer Institute's registered trials cover 20 conditions on ClinicalTrials.gov, led by Prostate Cancer (2 trials), Mesothelioma (2 trials), Kidney Cancer (2 trials), Colorectal Cancer (1 trial), metastatic-colon-cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Dana-Farber Cancer Institute clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 9 trials tracked for Dana-Farber Cancer Institute.